Interferons in the treatment of myeloproliferative neoplasms

Interferons in the treatment of myeloproliferative neoplasms

Interferons are cytokines with immunomodulatory properties and disease-modifying effects that have been used to treat myeloproliferative neoplasms (MPNs) for more than 35 years. The initial use of interferons was limited due to difficulties with administration and a significant toxicity profile. Man...

Full description

Bibliographic Details
Main Authors:	Pankit Vachhani, John Mascarenhas, Prithviraj Bose, Gabriela Hobbs, Abdulraheem Yacoub, Jeanne M. Palmer, Aaron T. Gerds, Lucia Masarova, Andrew T. Kuykendall, Raajit K. Rampal, Ruben Mesa, Srdan Verstovsek
Format:	Article
Language:	English
Published:	SAGE Publishing 2024-02-01
Series:	Therapeutic Advances in Hematology
Online Access:	https://doi.org/10.1177/20406207241229588

Similar Items

Novel Concepts of Treatment for Patients with Myelofibrosis and Related Neoplasms
by: Prithviraj Bose, et al.
Published: (2020-10-01)

Targeted therapies for myeloproliferative neoplasms
by: Bing Li, et al.
Published: (2019-07-01)

Treating accelerated and blast phase myeloproliferative neoplasms: progress and challenges
by: Helen O. Ajufo, et al.
Published: (2023-06-01)

Novel Therapies in Myeloproliferative Neoplasms: Beyond JAK Inhibitor Monotherapy
by: Sophia S. Lee, et al.
Published: (2021-08-01)

Use of Interferon Alfa in the Treatment of Myeloproliferative Neoplasms: Perspectives and Review of the Literature
by: Joan How, et al.
Published: (2020-07-01)

Novel therapeutics in myeloproliferative neoplasms
by: Sangeetha Venugopal, et al.
Published: (2020-12-01)

JAK Inhibition for the Treatment of Myelofibrosis: Limitations and Future Perspectives
by: Prithviraj Bose, et al.
Published: (2020-08-01)

MF management
by: Prithviraj Bose, et al.
Published: (2019-06-01)

Updates in the management of polycythemia vera and essential thrombocythemia
by: Prithviraj Bose, et al.
Published: (2019-08-01)

Long-acting interferon: pioneering disease modification of myeloproliferative neoplasms
by: Seug Yun Yoon, et al.
Published: (2023-11-01)

P1018: UPDATED RESULTS FROM MANIFEST ARM 2: EFFICACY AND SAFETY OF PELABRESIB (CPI-0610) AS ADD-ON TO RUXOLITINIB IN MYELOFIBROSIS
by: Marina Kremyanskaya, et al.
Published: (2023-08-01)

Characterization of disease-propagating stem cells responsible for myeloproliferative neoplasm–blast phase
by: Xiaoli Wang, et al.
Published: (2022-04-01)

Atypical Presentation of Erythroid/Megakaryocytic Leukemic Transformation of a Myeloproliferative Neoplasm Associated with Mutation and Loss of TP53
by: Brian J. Chernak, et al.
Published: (2020-08-01)

Myeloproliferative neoplasms
by: Jean-Jacques Kiladjian
Published: (2018-06-01)

Myeloproliferative neoplasms
by: Nick Cross, (Coordinating Author)
Published: (2019-06-01)

Interferon Alpha Therapy Increases Pro-Thrombotic Biomarkers in Patients with Myeloproliferative Neoplasms
by: Dorothée Faille, et al.
Published: (2020-04-01)

Association of Myelofibrosis Phenotypes with Clinical Manifestations, Molecular Profiles, and Treatments
by: Helen T. Chifotides, et al.
Published: (2023-06-01)

Momelotinib: an emerging treatment for myelofibrosis patients with anemia
by: Helen T. Chifotides, et al.
Published: (2022-01-01)

The microenvironment in myeloproliferative neoplasm
by: Simón Méndez-Ferrer, et al.
Published: (2018-06-01)

Spleen in myeloproliferative neoplasms
by: Giovanni Barosi
Published: (2018-06-01)

Aetiology of Myeloproliferative Neoplasms
by: Mary Frances McMullin, et al.
Published: (2020-07-01)

Epigenetics in myeloproliferative neoplasms
by: Graeme Greenfield, et al.
Published: (2023-07-01)

P1066: OUTCOMES OF COVID-19 IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS - AN OBSERVATIONAL COHORT STUDY FROM A LARGE ACADEMIC CANCER CENTER IN THE UNITED STATES
by: S. Venugopal, et al.
Published: (2022-06-01)

Dose‐dependent mathematical modeling of interferon‐α‐treatment for personalized treatment of myeloproliferative neoplasms
by: Rasmus K. Pedersen, et al.
Published: (2021-12-01)

Illuminating novel biological aspects and potential new therapeutic approaches for chronic myeloproliferative malignancies
by: Mughal, TI, et al.
Published: (2020)

Modifiable Lifestyle and Medical Risk Factors Associated With Myeloproliferative Neoplasms
by: Andrew S. Duncombe, et al.
Published: (2020-02-01)

Myeloproliferative neoplasm stem cells
by: Mead, A, et al.
Published: (2017)

Mutant Calreticulin in the Myeloproliferative Neoplasms
by: Daniel Prins, et al.
Published: (2020-02-01)

Neurological Findings in Myeloproliferative Neoplasms
by: Semra Paydas
Published: (2013-04-01)

CALR Mutations in Myeloproliferative Neoplasms
by: Ken-Hong Lim
Published: (2014-06-01)

New Perspectives of Interferon-alpha2 and Inflammation in Treating Philadelphia-negative Chronic Myeloproliferative Neoplasms
by: Hans C. Hasselbalch, et al.
Published: (2021-12-01)

Differential Dynamics of CALR Mutant Allele Burden in Myeloproliferative Neoplasms during Interferon Alfa Treatment.
by: Lasse Kjær, et al.
Published: (2016-01-01)

P986: COMBINATION JAK1/2 AND CDK8/19 INHIBITION DEMONSTRATES ENHANCED EFFICACY IN MYELOPROLIFERATIVE NEOPLASMS
by: Zachary Zaroogian, et al.
Published: (2023-08-01)

Tobacco use in the Myeloproliferative neoplasms: symptom burden, patient opinions, and care
by: Sarah F. Christensen, et al.
Published: (2021-06-01)

Classification and personalized prognosis in myeloproliferative neoplasms
by: Grinfeld, J, et al.
Published: (2018)

Heterogeneity in myeloproliferative neoplasms: causes and consequences
by: O'Sullivan, J, et al.
Published: (2018)

Mechanisms of disease transformation in myeloproliferative neoplasms
by: O'Sullivan, J
Published: (2022)

Functional Consequences of Mutations in Myeloproliferative Neoplasms
by: Stefan N. Constantinescu, et al.
Published: (2021-06-01)

Genetic Aspects of Myelodysplastic/Myeloproliferative Neoplasms
by: Laura Palomo, et al.
Published: (2021-04-01)

Clonal Hematopoiesis and Mutations of Myeloproliferative Neoplasms
by: Lasse Kjær
Published: (2020-07-01)